SecBot SecBot
8-K ·Filed Nov 12, 2026
AZ

AZR

Azora Therapeutics, Inc. (DE)
NEUTRAL
Impact 4/10
Horizonmonths Processed5d 1h ago SEC0001213900-26-118922
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the December 11, 2026 stockholder approval deadline for Series A conversion and potential $51.9M cash settlement risk. Track any milestone warrant exercise announcements for up to $32.4M in additional funding. The next catalyst is the AT177 IND submission in H1 2027.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$4.09
T+0 close · Nov 12, 2026 · via day close
Latest settled
−6.85%
T+1 · $3.81
Vs SPY
−4.93%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $4.09entry
  2. T+1 · yesterday −6.85%α −4.93% · $3.81
  3. T+2 · todayOpen
  4. T+5 · in 3d Pending
  5. T+20 · in 27d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Azora Therapeutics (formerly Adial Pharmaceuticals) reported Q3 2026 results post-merger: net loss of $64.6M ($4.52 per share) vs $1.8M ($2.02 per share) a year ago, driven by a $57.1M non-cash fair value charge on milestone warrant rights. Cash burn was $6.7M QoQ to $22.0M. The company is now trading as AZR on Nasdaq with a new CEO, CFO, and board. AT177 IND submission and Phase 1a remain on track for H1 2027. No consensus estimates were provided for comparison.

Key Financial Metrics

EPS
−$4.52

Key Facts

  • Net loss of $64.6M ($4.52 per share) for Q3 2026, including a $57.1M non-cash charge for change in fair value of milestone warrant rights liability
  • Cash and cash equivalents $22.0M as of September 30, 2026, down from $28.7M at June 30, 2026
  • R&D expenses increased to $1.8M from $0.5M year-over-year; G&A expenses increased to $5.8M from $1.2M
  • Company changed name from Adial Pharmaceuticals to Azora Therapeutics and began trading as AZR on Nasdaq on October 29, 2026
  • New executive team and board appointed; 9.9M shares of Series A preferred converted to common stock on November 2, 2026
  • AT177 IND submission and Phase 1a trial planned for first half of 2027
  • Up to $32.4M in potential gross proceeds from milestone warrant purchases if investors elect to exercise
  • Stockholders' deficit of $21.1M as of September 30, 2026, primarily due to $38.5M Series A preferred classified as temporary equity

Financial Impact

Net loss of $64.6M in Q3 2026, cash burn of $6.7M from $28.7M to $22.0M during the quarter

net losscash positionoperating expenses

Risk Factors

  • Stockholders' deficit of $21.1M and going concern risk; company may need additional capital before AT177 reaches clinical data
  • Potential $51.9M cash settlement obligation if stockholder approval for Series A conversion is not obtained by December 11, 2026
  • Massive potential dilution from up to 25.1M shares registered for resale (nearly 10x current shares outstanding) per the S-3/A filed October 20, 2026
  • Nasdaq delisting risk remains unresolved; material weakness in internal control over financial reporting identified

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-118922
Document: ea0311952-8k_azora.htm0001213900-26-118922
Document: 0001213900-26-118922-index-headers.html0001213900-26-118922
Document: 0001213900-26-118922-index.html0001213900-26-118922
Document: 0001213900-26-118922.txt0001213900-26-118922
8-K Data (Synthetic)0001213900-26-118922

Track record

5 reports on AZR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today S-3 Bearish 6/10 Entry $3.81 Now $3.66 +3.81% settles Nov 24
  2. Nov 12, 20265d ago 8-K Neutral 4/10 Viewing Entry $4.09 Now $3.66 −10.39% settles Nov 20
  3. Nov 10, 20267d ago 3 Neutral 2/10 Entry $3.76 to $3.67 Now $3.66 −2.53% ▼ −2.53% −0.20% vs SPY
  4. Nov 9, 20268d ago 8-K Neutral 4/10 Entry $3.75 to $3.81 Now $3.66 −2.27% ▲ +1.60% +3.29% vs SPY
  5. Nov 3, 202614d ago SC 13G/A Bearish 4/10 Entry $4.15 to $3.76 Now $3.66 +11.69% ▲ +9.40% +8.81% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026